VanEck reports that major pharmaceutical firms are being reassessed by investors following advancements in GLP-1, artificial intelligence in drug discovery, and shifts in healthcare consumption habits. The reassessment has been prompted by the sector experiencing significant changes that are driving interest and scrutiny.